Prognostic role of CD133 expression in colorectal cancer: A meta-analysis

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Wang, Ke ^a   Xu, Jianjun ^b   Zhang, Junshu ^a,c   Huang, Jian ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY OF FINANCE AND ECONOMICS   (China)

^c Linan People's Hospital   (China)

Author keywords

Cancer stem cell; CD133; Colorectal cancer; Prognosis

Indexed keywords

CD133 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CORRELATION ANALYSIS; ENZYME ACTIVITY; HUMAN; LYMPH NODE METASTASIS; RISK FACTOR; TUMOR DIFFERENTIATION;

ANTIGENS, CD; COLORECTAL NEOPLASMS; GLYCOPROTEINS; HUMANS; LYMPHATIC METASTASIS; NEOPLASTIC STEM CELLS; PEPTIDES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870308683     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-573     Document Type: Article

References (30)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111. 10.1038/35102167, 11689955.
2. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol 2007, 18:460-466. 10.1016/j.copbio.2007.10.007, 18023337.
3. Wang K, Liu L, Zhang T, Zhu YL, Qiu F, Wu XG, Wang XL, Hu FQ, Huang J. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer. Int J Nanomedicine 2011, 6:3207-3218. 3254265, 22238509.
4. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009, 14:3-9. 10.1007/s10911-009-9109-9, 19224345.
5. Fulda S, Pervaiz S. Apoptosis signaling in cancer stem cells. Int J Biochem Cell Biol 2010, 42:31-38. 10.1016/j.biocel.2009.06.010, 19577660.
6. Rich JN, Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell 2007, 1:353-355. 10.1016/j.stem.2007.09.011, 18371369.
7. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997, 90:5002-5012.
8. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 2000, 97:14720-14725. 10.1073/pnas.97.26.14720, 18985, 11121071.
9. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946-10951. 10.1158/0008-5472.CAN-05-2018, 16322242.
10. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115. 10.1038/nature05384, 17122771.
11. Galizia G, Gemei M, Del Vecchio L, Zamboli A, Di Noto R, Mirabelli P, Salvatore F, Castellano P, Orditura M, De Vita F, et al. Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer. Arch Surg 2012, 147:18-24. 10.1001/archsurg.2011.795, 22250106.
12. Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 2008, 99:1578-1583. 10.1111/j.1349-7006.2008.00849.x, 18754869.
13. Zhou L, Jiang Y, Yan T, Di G, Shen Z, Shao Z, Lu J. The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures. Breast Cancer Res Treat 2010, 122:795-801. 10.1007/s10549-010-0999-4, 20571867.
14. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834. 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8, 9921604.
15. Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L, Zlobec I. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010, 103:382-390. 10.1038/sj.bjc.6605762, 2920016, 20606680.
16. Takahashi S, Kamiyama T, Tomaru U, Ishizu A, Shida T, Osaka M, Sato Y, Saji Y, Ozaki M, Todo S. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Oncol Rep 2010, 24:1201-1212.
17. Li CY, Li BX, Liang Y, Peng RQ, Ding Y, Xu DZ, Zhang X, Pan ZZ, Wan DS, Zeng YX, et al. Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med 2009, 7:56. 10.1186/1479-5876-7-56, 2715381, 19583834.
18. Xi HQ, Zhao P. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol 2011, 64:498-503. 10.1136/jcp.2010.087213, 21415057.
19. Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R, Salto-Tellez M. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol 2010, 23:450-457. 10.1038/modpathol.2009.181, 20081809.
20. Wang Q, Chen ZG, Du CZ, Wang HW, Yan L, Gu J. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Histopathology 2009, 55:284-293. 10.1111/j.1365-2559.2009.03378.x, 19723143.
21. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 2009, 27:844-850. 10.1080/07357900902744502, 19626493.
22. Coco C, Zannoni GF, Caredda E, Sioletic S, Boninsegna A, Migaldi M, Rizzo G, Bonetti LR, Genovese G, Stigliano E, et al. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. J Exp Clin Cancer Res 2012, 31:71. 10.1186/1756-9966-31-71, 22964035.
23. Hongo K, Kazama S, Sunami E, Tsuno NH, Takahashi K, Nagawa H, Kitayama J. Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer. Med Oncol 2012, 29:2849-2857. 10.1007/s12032-012-0161-8, 3466429, 22246526.
24. Zhang NH, Li J, Li Y, Zhang XT, Liao WT, Zhang JY, Li R, Luo RC. Co-expression of CXCR4 and CD133 proteins is associated with poor prognosis in stage II-III colon cancer patients. Exp Ther Med 2012, 3:973-982.
25. Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH, Song YS, Jang KS, Paik SS. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009, 15:2258-2264. 10.3748/wjg.15.2258, 2682242, 19437567.
26. Ieta K, Tanaka F, Haraguchi N, Kita Y, Sakashita H, Mimori K, Matsumoto T, Inoue H, Kuwano H, Mori M. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 2008, 15:638-648. 10.1245/s10434-007-9605-3, 17932721.
27. Artells R, Moreno I, Diaz T, Martinez F, Gel B, Navarro A, Ibeas R, Moreno J, Monzo M. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients. Eur J Cancer 2010, 46:642-649. 10.1016/j.ejca.2009.11.003, 20005089.
28. Vogler T, Kriegl L, Horst D, Engel J, Sagebiel S, Schaffauer AJ, Kirchner T, Jung A. The expression pattern of aldehyde dehydrogenase 1 (ALDH1) is an independent prognostic marker for low survival in colorectal tumors. Exp Mol Pathol 2012, 92:111-117. 10.1016/j.yexmp.2011.10.010, 22101256.
29. Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, LaBonte MJ, Wilson PM, Benhaim L, Paez D, et al. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res 2011, 17:6934-6943. 10.1158/1078-0432.CCR-11-1180, 21918173.
30. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012, 22:457-472. 10.1038/cr.2012.13, 22357481.